NASDAQ:ACAD
Acadia Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc.'s revenue grew 11.9% in fiscal 2025 to $1.1B while operating margin fell to 9.8%. Free cash flow was $105.1M, 9.8% of revenue, and the diluted share count rose 2.1%.Summary generated from Acadia Pharmaceuticals Inc.'s SEC filings. Latest annual report filed Feb 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$1.1B
Revenue growth+11.9%
Revenue, 5-yr CAGR+19.4%
Gross margin91.7%
Operating margin9.8%
Net margin36.5%
ROICn/a
Return on equity39.9%
Debt / equityn/a
Free cash flow$105.1M
FCF margin9.8%
Share count change+2.1%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 484 | 517 | 726 | 958 | 1,072 |
| Operating income | −170 | −224 | −73 | 231 | 105 |
| Net income | −168 | −216 | −61 | 226 | 391 |
| Free cash flow | −127 | −114 | 17 | 157 | 105 |
Recent filings
- 8-KRegulation FD disclosure
Sep 24, 2026 - 8-KOther events
Sep 11, 2026 - 4Insider transaction report
Aug 7, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 5, 2026 - 8-KResults of operations and financial condition
Aug 4, 2026 - 4Insider transaction report
Jul 31, 2026 - 8-KDirector or officer change
May 29, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 7, 2026